Bladder cancer (BC) is the second-most common cancer of the genitourinary tract and also the major cause of death in patients. Preventing BC is highly desirable to reduce recurrence, mortality and improve quality of life. Preclinical and clinical data indicate the potential role of AR signaling in different stages of BC. In view of the strong link between AR signals and bladder cancer progression, apalutamide, a FDA approved next-generation AR antagonist, could provide a preventive strategy in NMIBC to mitigate progression to MIBC. The overall objective of this task order is to determine the efficacy of Apalutamide against N-butyl-N(4-hydroxybutyl) nitrosamine (BBN) induced rat urinary bladder cancers. The task order will assess welldefined predictive biomarkers of bladder cancer inhibition by apalutamide.